Barnes RP, de Rosa M, Thosar SA, Detwiler AC, Roginskaya V, Van Houten B, et al
Intermediate Protocol After establishing tolerance, add weekly microneedling with a 0.25-0.5mm dermaroller
CCAT1 promotes hepatocellular carcinoma cell proliferation and invasion
The top 4 candidate biomarkers of interest identified here belong to different molecular categories (miRNAs, extra-cellular matrix, and cytokines), and are involved in pathophysiological processes common to many diseases, especially extra-cellular matrix remodeling and inflammation
At 72 weeks: 62.9% of semaglutide patients achieved resolution of MASH without worsening of fibrosis, compared to approximately 34% on placebo Semaglutide demonstrated significant improvements in both MASH activity and liver fibrosis an outcome that distinguished it from the Phase 2 results where fibrosis improvement was less clear On August 15, 2025, the FDA granted accelerated approval to semaglutide (Wegovy
